1999•PubMedRequires access

[Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma].

Pieter Sonneveld, P.C. Huijgens, Anton Hagenbeek

Abstract

The treatment of choice for patients over 60 years of age with aggressive non-Hodgkin's lymphoma (NHL) consists of chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Because of poor tolerance, dose reductions and delays occur frequently. However, because of the relatively low dose intensity significantly more patients die of refractory or relapse lymphoma. If it is intended to cure these patients, unmitigated CHOP chemotherapy should be applied. When needed additional supportive care can be provided.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, Vincristine, CHOP, Prednisone, Lymphoma, Chemotherapy, Cyclophosphamide, Doxorubicin